The inhibitors of BET proteins represent a promising class of therapeutic agents that target the oncogenic activity of MYC and repress DLBCL cell migration, but the mechanism of such repression remains elusive. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.